BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 23, Issue 32
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (16536)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.
Item 
Count 
PDF1320
WORD235
HTML10686
Figures (1-1)600
Tables (1-3)586
 Sum=13427
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1322
Download1787
 Sum=3109
Aug 28, 2017 (publication date) through Nov 11, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
Copyright ©The Author(s) 2017.
World J Gastroenterol. Aug 28, 2017; 23(32): 5875-5886
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875
Table 1 Patients characteristics in metastatic pancreatic cancer pivotal trials
GemcitabineFOLFIRINOXNab-paclitaxel + gemcitabine
Trial (yr)Gemcitabine vs 5-fluorouracil (1997)FOLFIRINOX vs Gemcitabine (2011)Nab-paclitaxel + Gemcitabine vs Gemcitabine (2013)
Phase1II-IIIIII
CountriesUnited states-Canada-United KingdomFranceWorldwide
Patients126342861
Median age61.56162
Elderly ( ≥ 75 yr)YesYes
ECOG PS 0-1YesYesYes
ECOG PS 2YesYes
Biliary StentYesYesYes
Multiple metastatic sitesYesYesYes
1Phase not specified in the full paper. ECOG PS: Eastern Cooperative Oncology Group Performance Status.
Full Size Table
Table 2 Principal clinical trials with nab-paclitaxel in metastatic pancreatic cancer
Study IDSettingStudy drugsPhaseStatus
NCT02993731MetastaticNab-paclitaxel + Gemcitabine +/-NapabucasinIIIRecruiting
NCT02101021MetastaticNab-paclitaxel + Gemcitabine +/- MomelotinibIIIActive not recruiting
NCT02715804MetastaticNab-paclitaxel + Gemcitabine +/-PEGPH20IIIRecruiting
NCT02436668MetastaticNab-paclitaxel + Gemcitabine +/- IbrutinibII-IIIRecruiting
NCT02827201MetastaticSequential Nab-paclitaxel + Gemcitabine /FOLFIRIIIActive not recruiting
NCT02767557MetastaticNab-paclitaxel + Gemcitabine +/-tocilizumabIIRecruiting
NCT03086369MetastaticNab-paclitaxel + Gemcitabine +/- OlaratumabIINot yet recruiting
NCT02879318MetastaticNab-paclitaxel + Gemcitabine +/- Durvalumab + TremelimumabIIRecruiting
NCT02399137MetastaticNab-paclitaxel + Gemcitabine +IIRecruiting
MM-141
NCT02340117MetastaticNab-paclitaxel + Gemcitabine +IIRecruiting
SGT-53
NCT02124317MetastaticNab-paclitaxel + S-1IIActive not recruiting
NCT03076216MetastaticNab-paclitaxel + Gemcitabine + ONCOsilIINot yet recruiting
NCT02905578MetastaticNab-paclitaxel + Gemcitabine +IINot yet recruiting
High-dose ascorbate
NCT02732938MetastaticNab-paclitaxel + Gemcitabine + PF-04136309IIRecruiting
NCT02551991MetastaticNal-Iri or Gemcitabine +IIRecruiting
Nab-paclitaxel
NCT03009058MetastaticNab-paclitaxel + Gemcitabine +I-IINot yet recruiting
IMM 101
NCT02559674MetastaticNab-paclitaxel + Gemcitabine +I-IIRecruiting
ALT-803
NCT02705196MetastaticNab-paclitaxel + Gemcitabine + LOAd703 oncolytic virusI-IIRecruiting
NCT01834235MetastaticNab-paclitaxel + Gemcitabine +I-IIActive not recruiting
NPC-1C
NCT01730222MetastaticNab-paclitaxel + Gemcitabine + Capecitabine + CisplatinI-IIRecruiting
NCT02620800MetastaticNab-paclitaxel + 5-fluorouracil + Leucovorin + Bevacizumab + OxaliplatinI-IIRecruiting
NCT01506973MetastaticNab-paclitaxel + Gemcitabine + HydroxychloroquineI-IIRecruiting
NCT02504333MetastaticNab-paclitaxel + Gemcitabine followed by FOLFOXI-IIRecruiting
NCT02050178MetastaticNab-paclitaxel + Gemcitabine + OMP-54F28IActive not recruiting
NCT02309177MetastaticNab-paclitaxel + Nivolumab +/- GemcitabineIRecruiting
NCT02514031MetastaticNab-paclitaxel + Gemcitabine +IRecruiting
ARQ-761
NCT01934634MetastaticNab-paclitaxel + Gemcitabine + LCL161IActive not recruiting
NCT02101580MetastaticNab-paclitaxel + Gemcitabine +IActive not recruiting
ADI-PEG 20
NCT02138383MetastaticNab-paclitaxel + Gemcitabine + EnzalutamideIActive not recruiting
NCT02975141MetastaticNab-paclitaxel + Gemcitabine + AfatinibIRecruiting
NCT02227940MetastaticNab-paclitaxel + Gemcitabine + CeritinibIRecruiting
NCT02231723MetastaticNab-paclitaxel + Gemcitabine +IRecruiting
BBI608
NCT02501902MetastaticNab-paclitaxel + PalbociclibIRecruiting
Nal-Iri: Nanoliposomal irinotecan.
Full Size Table
Table 3 Principal clinical trials with nab-paclitaxel in pancreatic cancer “early settings”
Study IDSettingStudy drugsPhaseStatus
NCT01964430AdjuvantNab-paclitaxel + Gemcitabine vs GemcitabineIIIRecruiting
NCT02506842AdjuvantNab-paclitaxel + Gemcitabine vs OFFIIIRecruiting
NCT02023021AdjuvantNab-paclitaxel + GemcitabineIIRecruiting
NCT02125136NeoadjuvantNab-paclitaxel + Gemcitabine vs FOLFIFINOXIIRecruiting
NCT02243007NeoadjuvantNab-paclitaxel + Gemcitabine vs FOLFIFINOXIIRecruiting
NCT02717091Neoadjuvant/borderline resectableNab-paclitaxel + Gemcitabine vs FOLFIFINOXIIRecruiting
NCT02481635NEO/adjuvantNab-paclitaxel + Gemcitabine + radiotherapyI-IIRecruiting
NCT01431794NeoadjuvantNab-paclitaxel + Gemcitabine + LDE-225I-IIActive not recruiting
NCT02588443NEO/adjuvantNab-paclitaxel + Gemcitabine + RO7009789IRecruiting
NCT02272738NeoadjuvantNab-paclitaxel + Gemcitabine + radiotherapyIRecruiting
NCT02506803NeoadjuvantNab-paclitaxel + GemcitabineIRecruiting
NCT02427841ResectableNab-paclitaxel + Gemcitabine followed by radiotherapyIIRecruiting
NCT02550327ResectableNab-paclitaxel + Gemcitabine + Cisplatin + AnakinraIRecruiting
NCT02210559Locally advancedNab-paclitaxel + Gemcitabine + FG-3019I-IIRecruiting
NCT02394535Locally advancedNab-paclitaxel + Capecitabine + radiotherapyIRecruiting
NCT02124369Borderline unresectableNab-paclitaxel + GemcitabineIIRecruiting
NCT02043730Unresectable locally advacedNab-paclitaxel + GemcitabineIIRecruiting
NCT02207465Unresectable locally advancedNab-paclitaxel + Gemcitabine + radiotherapyIRecruiting
NCT02272738Unresectable locally advancedNab-paclitaxel + GemcitabineIRecruiting
NCT01978184PreoperativeNab-paclitaxel + Gemcitabine + HydroxychloroquineIIRecruiting
NCT02427841PreoperativeNab-paclitaxel + Gemcitabine + radiotherapyIIRecruiting
NCT02723331PreoperativeNab-paclitaxel + Gemcitabine followed by SBRTIIRecruiting
NCT02930902PreoperativeNab-paclitaxel + Gemcitabine + Pembrolizumab + ParicalcitolIRecruiting
SBRT: Stereotactic body radiotherapy; OFF: Oxaliplatin plus fluoro-folate.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345